Tandem Diabetes Care Stock Forecast, Price & News

Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care or view top-rated stocks.

How has Tandem Diabetes Care's stock price been impacted by COVID-19 (Coronavirus)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TNDM stock has increased by 93.8% and is now trading at $128.52.
View which stocks have been most impacted by COVID-19.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Tandem Diabetes Care.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) posted its earnings results on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to the consensus estimate of $172.80 million. Tandem Diabetes Care had a net margin of 3.29% and a trailing twelve-month return on equity of 6.85%. During the same quarter in the previous year, the business posted ($0.09) EPS.
View Tandem Diabetes Care's earnings history.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $685 million-$695 million, compared to the consensus revenue estimate of $684.32 million.

What price target have analysts set for TNDM?

8 Wall Street analysts have issued twelve-month price objectives for Tandem Diabetes Care's stock. Their forecasts range from $90.00 to $153.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $136.00 in the next twelve months. This suggests a possible upside of 5.8% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:

• John F. Sheridan, President, Chief Executive Officer & Director
• James Leal, Senior Vice President-Operations (LinkedIn Profile)
• Leigh A. Vosseller, CFO, Treasurer, Principal Accounting Officer & EVP (LinkedIn Profile)
• Manuel Jaime, Senior Vice President-Technology & Digital Health
• Michael Michaud, Vice President-Research & Development

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Who are some of Tandem Diabetes Care's key competitors?

Some companies that are related to Tandem Diabetes Care include Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Abiomed (ABMD), Teleflex (TFX), Hill-Rom (HRC), NovoCure (NVCR), Penumbra (PEN), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Beauty Health (SKIN) and Merit Medical Systems (MMSI).
View all of TNDM's competitors.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.14%), Capital World Investors (5.18%), Invesco Ltd. (2.73%), RTW Investments LP (1.83%), Credit Suisse AG (1.63%) and Bellevue Group AG (1.63%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

Which institutional investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Assenagon Asset Management S.A., Point72 Asset Management L.P., TimesSquare Capital Management LLC, Bank of Nova Scotia, American Century Companies Inc., Wellington Management Group LLP, and Eaton Vance Management. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, James Leal, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care or view top insider-selling stocks.

Which institutional investors are buying Tandem Diabetes Care stock?

TNDM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Goldman Sachs Group Inc., Bank of New York Mellon Corp, Principal Financial Group Inc., Renaissance Technologies LLC, Invesco Ltd., Kingdon Capital Management L.L.C., and American International Group Inc..
View insider buying and selling activity for Tandem Diabetes Care or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $128.52.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $8.17 billion and generates $498.83 million in revenue each year. The medical device company earns $-34.38 million in net income (profit) each year or $0.29 on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,500 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].